This is a non-core endpoint: only basic statistics are computed.
Severe combined immunodeficiency [SCID] with low or normal B-cell numbers
D3_SCIDC
No definition available.
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule None
429209
Check conditions None
429209
Check pre-conditions, main-only, mode, registry filters
2 out of 7 registries used, show all original rules.
17
Check minimum number of events None
17
Include endpoints None
17
Remove individuals based on genotype QC
15
D3_SCIDC
Control definitions
Control exclude
D3_IMMUNEMECHANISM
Extra metadata
Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D81
Name in latin
Deficientia immunalis mixta gravis cum deficientia sive numero normali cellularum B
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Severe combined immunodeficiency [SCID] with low or normal B-cell numbers
based on the number of shared cases.
Broader endpoints:
- Combined immunodeficiencies
- Immunodeficiencies
- Certain disorders involving the immune mechanism
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Any operation in hilmo
Narrower endpoints:
None
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 15 | 12 | - |
| Unadjusted prevalence (%) | 0.00 | 0.01 | - |
| Mean age at first event (years) | 52.04 | 50.46 | - |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: D3_SCIDC – Severe combined immunodeficiency [SCID] with low or normal B-cell numbers
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Severe combined immunodeficiency [SCID] with low or normal B-cell numbers
↥Endpoint not on priority list, no data to show.